Effert compartion of vertebral artery atherosclerotic stenosis by ISR and drug treatment
LI Xiaoyong1 LIN Jianmei2
1.Department of Neurology, the First People′s Hospital of Ziyang, Sichuan Province, Ziyang 641300, China;
2.Department of Nephrology, the First People′s Hospital of Ziyang, Sichuan Province, Ziyang 641300, China
Abstract:Objective To investigate the effect of vertebral artery stenting and drug therapy on vertebral artery atherosclerosis stenosis. Methods The clinical data of 80 patients with vertebral artery atherosclerotic stenosis from January 2012 to December 2017 in the First People′s Hospital of Ziyang of Sichuan Province were retrospectively analyzed. They were divided into control group (given drug treatment) and observation group (given vertebral artery stenting) according to the treatment method, 40 cases in each group. Relative cerebral blood flow (rCBF), relative mean transit time (rMTT), relative cerebral blood volume (rCBV) and relative peak time (rTTP) were observed before and after treatment in the two groups. The clinical efficacy, stroke and mortality in the two groups were observed after 6 months. Results There was no significant difference in rCBF, rMTT, rCBV and rTTP between the two groups before and after treatment (P > 0.05); there was no significant difference in rCBF, rMTT, rCBV and rTTP in the control group before and after treatment (P > 0.05); there was no significant difference in rCBV in the observation group before and after treatment (P > 0.05); after treatment, rCBF in the observation group was higher, while rMTT, rTTP were lower than before treatment, the difference were statistical significance (P > 0.05). The clinical treatment efficiency of the observation group was higher than that of the control group, the difference was statistically significant (P < 0.05). There was no significant difference in stroke and mortality between the two groups 6 months after treatment (P > 0.05). Conclusion Vertebral artery stenting can significantly improve rCBF, rMTT and rTTP in patients with vertebral artery atherosclerotic stenosis, and its clinical effect is good, which is worthy of clinical application.
李小勇1 林建美2. 椎动脉支架成形术和药物治疗椎动脉动脉粥样硬化狭窄的效果比较[J]. 中国医药导报, 2019, 16(11): 126-129.
LI Xiaoyong1 LIN Jianmei2. Effert compartion of vertebral artery atherosclerotic stenosis by ISR and drug treatment. 中国医药导报, 2019, 16(11): 126-129.
[1] Siebler M,Hennerici MG,Schneider D,et al. Safety of tirofiban acute ischemic stroke:the satis trial [J]. Stroke,2011,42(9):2388-2392.
[2] 刘洁,郑立建,佟小光,等.分期椎动脉支架置入术和颈动脉内膜剥脱术治疗椎动脉并颈动脉粥样硬化狭窄[J].山东医药,2016,56(43):68-70.
[3] 韩丽丽,陈玲.辛伐他汀强化降脂对椎动脉支架植入术后再狭窄的影响[J].中国实用神经疾病杂志,2016,19(8):46-47.
[4] Tsai CF,Anderson N,Thomas B,et al. Risk factors for ischemic stroke and its subtypes in Chinese vs.Caucasians:systematicreview and meta-analysis [J]. Int J Stroke,2015, 10(4):485-493.
[5] 谭凯儒,李艳萍,椎动脉支架置入术对脑血管反应性的影响[J].中国实用神经疾病杂志,2016,19(23):108-109.
[6] Gulli G,Marquardt L,Rothwell PM,et al. Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis:pooled data analysis from prospective studies [J]. Stroke,2013,44(3):598-604.
[7] 周峰,马黎,傅国萍,等.椎动脉支架置人术的临床长期随访[J].中华老年心脑血管病杂志,2018,20(5):517-521.
[8] Chang JY,Jung S,Jung C,et al. Dominant vertebral artery status and functional outcome after endovascular therapy of symptomatic basilar artery occlusion [J]. J Neuroradiol,2017,44(2):151-157.
[9] 王铁军,石富铭,陈书阁,等.椎动脉支架置入术对颅内椎动脉狭窄患者血流动力学的影响及术后再狭窄的影响因素研究[J].实用心脑肺血管病杂志,2016,24(1):37-40.
[10] Miao Z,Zhang Y,Shuai J,et al. Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China [J]. Stroke,2015,46(10):2822-2829.
[11] 周琳,唐维国,管姝轶,等.经肱动脉行同侧椎动脉支架成形术治疗椎动脉狭窄的可行性分析[J].中国现代医生,2018,56(4):1-4.
[12] Wang X,Wang Z,Wang C,et al. Application of the enterprise stent in atherosclerotic intracranial arterial stenosis:A series of 60 cases [J]. Turk Neurosurg,2016, 26(1):69-76.
[13] 赵宇,金旻,王佳楠,等.支架成形术治疗老年症状性颅内椎动脉粥样硬化性重度狭窄长期随访结果[J].中华老年心脑血管病杂志,2017,19(7):681-684.
[14] Duan G,Feng Z,Zhang L,et al. Solitaire stents for the treatment of complex symptomatic intracranial stenosis after antithrombotic failure:Safety and efficacy evaluation [J]. J Neurointerv surg,2016,8(7):680-684.
[15] 于江华,史志勤,苏旭东,等.颅内段椎动脉支架内再狭窄所致慢性闭塞的血管内再通治疗[J].脑与神经疾病杂志,2018,26(5):319-323.
[16] 史亚娜,王效增,杜占奎,等.椎动脉支架植入术治疗椎动脉狭窄的疗效[J].心血管康复医学杂志,2015,24(2):179-181.
[17] 李国锋,李震中,魏玉清,等.阿托伐他汀钙联合普罗布考预防椎动脉支架术后再狭窄及相关研究[J].河北医药,2018,40(5):649-654.
[18] Compter A,van der Worp HB,Schonewille WJ,et al. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis:a randomised open-label phase 2 trial [J]. Lancet Neurol,2015,14(6):606-614.
[19] 蓝香琳,王恰如.椎动脉支架植入术治疗椎动脉粥样硬化性狭窄的研究概况[J].中国临床新医学,2017,10(10):1019-1022.
[20] 米玉霞,张广玉,王艳玲,等.血管内治疗联合药物治疗与单纯药物治疗重度椎动脉起始段狭窄患者的卒中复发率的比较研究[J].临床和实验医学杂志,2017,16(2):181-184.
[21] 段春苗,王铁军,陈书阁,等.颅内外血管狭窄支架置入术后再狭窄的相关因素研究[J].中国医学装备,2018, 15(6):50-53.
[22] Geng X,Hussain M,Du H,et al. Comparison of self-expanding stents with distal embolic protection to balloon-expandable stents without a protection device in the treatment of symptomatic vertebral artery origin stenosis:a prospective randomized trial [J]. J Endovasc Ther,2015, 22(3):436-444.